STORM in the News

Royal Society of Chemistry: Designing cancer drugs

David Hardick, Director, Medicinal Chemistry spoke with Andy Extance, Royal Society of Chemistry on chemistry's role in cancer therapy and talks about how through screening, STORM identified first-in-class inhibitors of METTL3, effective against AML. STORM has now selected its first-in-class drug candidate, STC-15 for development towards first in human clinical studies in 2022.

To read the full article, please click here.

RNA Epigenetics in Human Disease

A STORM Therapeutics conference | 2022 Dates To be Confirmed